Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Up 6.8 %

NASDAQ:CYCC opened at $0.32 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.29 and a 12 month high of $4.00. The stock has a 50 day moving average of $0.34 and a two-hundred day moving average of $0.54. The firm has a market cap of $2.01 million, a P/E ratio of -0.03 and a beta of 0.28.

Insiders Place Their Bets

In other news, CEO David E. Lazar sold 194,628,820 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.97% of the stock is owned by company insiders.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.